Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Dana-Farber Cancer Institute, University of Michigan, UNC Lineberger Comprehensive Cancer Center, Duke University, Memorial Sloan Kettering Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2242881904